Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

Front Pharmacol. 2024 Nov 11:15:1519505. doi: 10.3389/fphar.2024.1519505. eCollection 2024.

Authors

Lu Li¹, Shilei Yang¹, Fengqi Fang², Li Tian¹, Ying He¹, Jia Li², Yanwei Chen¹, Deshi Dong¹

Affiliations

¹ Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China.
² Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2024.1382120.].

Keywords: HER-2-positive metastatic breast cancer; T-DM1; T-DXd; cost-effectiveness analysis; network meta-analysis; pyrotinib plus capecitabine.

Copyright © 2024 Li, Yang, Fang, Tian, He, Li, Chen and Dong.

Publication types

Published Erratum